Compare NTCT & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTCT | SRPT |
|---|---|---|
| Founded | 1984 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1999 | 2000 |
| Metric | NTCT | SRPT |
|---|---|---|
| Price | $33.16 | $14.16 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 24 |
| Target Price | ★ $42.50 | $21.86 |
| AVG Volume (30 Days) | 435.5K | ★ 1.5M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.39 | N/A |
| EPS | 0.76 | ★ 2.78 |
| Revenue | $891,820,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $4.76 | N/A |
| Revenue Next Year | $2.48 | N/A |
| P/E Ratio | $42.59 | ★ $5.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.29 | $14.59 |
| 52 Week High | $45.28 | $24.68 |
| Indicator | NTCT | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 37.65 | 28.61 |
| Support Level | $31.44 | N/A |
| Resistance Level | $34.14 | $18.26 |
| Average True Range (ATR) | 1.43 | 0.84 |
| MACD | -0.13 | -0.37 |
| Stochastic Oscillator | 26.99 | 0.48 |
NetScout Systems Inc is engaged in providing enterprise network observability, carrier service assurance, cybersecurity, and Distributed Denial-of-Service (DDoS), protection solutions. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.